On the site of the event,

three innovative financial products are released,

including Chengdu Tao Guosheng Healthcare Equity Investment fund, BIO “investment-based loan”,

 

and “clinical research expense loss insurance”.

They expand investment and financing channels for enterprises from the fields of fund, credit loan and insurance,

promoting their development and growth.

   

 

 

       "Clinical research expense loss insurance"

 

       The “clinical research expense loss insurance” provides a guarantee for enterprises entering the clinical phase. If an enterprise fails in clinical trials, it can obtain the insurance support and the capital for starting again. This product was filed by PICC at China Banking and Insurance Regulatory Commission, and PICC took the lead in giving Chengdu Borns (TM) Medical Robotics Inc. the sum insured of RMB 5 million.

 

       How to determine?

       For R&D and innovation projects in the fields of biological medicine and medical devices, as long as they meet the requirements of national relevant laws and regulations, clinical trials will be allowed for them in hospitals with GCP qualification in China. The loss of R&D expenses shall be determined by whether the conclusion of the statistical analysis report has achieved the clinical trial goal, and whether the conclusion can support the sponsor to obtain the approval of the next stage of research or obtain the production approval. The conclusion of the report shall be the sole judgment basis for triggering the insurance liability of the policy.

 

 

 

2021 CDHT Bioindustry Investment and Financing Road Show Phase VIII was also held on the site.

The activity was held in the form of “offline road show + online live streaming”.

High-quality projects of enterprises were selected for a wonderful road show.

Leaders of well-known institutions in the industry were invited as judges for one-to-one professional comments.

 

 

       BIO-LINK investment and financing road show activity

       It is an exchange platform between bioindustry enterprises and investment institutions which is set up by CDHT in the form of road show. The activity aims to promote the effective connection of high-quality biomedical projects with investment and financing experts and industry experts, and drive the high-quality development of regional bioindustry.

 

       All representatives attending the road show have made contributions in the field of original new drugs. The five projects brought by Xiling Lab, Life Baseline, Chengdu Organochem Co., Ltd., Sichuan Yiai Technology Co., Ltd., and Chengdu Xinrui Taikang Technology Co., Ltd. fully demonstrate their key technologies of R&D and industrialization of original new drugs. The experts attending the meeting made comments and exchanges on the core technologies of the projects, team support, and development plans.

 

       “BIO-LINK activity has provided much convenience for corporate financing. Companies can connect with multiple investment institutions at one time, improving the communication efficiency. Besides, the entities of the original new drug road show activity can exchange with other industry experts and negotiate on cooperation, benefiting a lot - said Prof. Huang Jinkun, Founder of Xiling Lab.”

 

 

       In recent years, CDHT has kept innovating in financial products, improving the service mode and setting up service platforms. A “fund-credit-insurance” trinity characteristic industrial financial system has been established for industry development.

 

       As one of the three leading industries, the medical and health industry in CDHT is developing rapidly. The industrial ecosystem leads the high-quality development of industrial functional zones, and promotes the integration of “five chains”: industrial chain, factor chain, supply chain, value chain and innovation chain. In 2020, the scale of the medical and health industry broke through RMB 60 billion, ranking the third place among nationwide biomedical industrial parks, and becoming a new highland for the development of medical and health industry nationwide.

 

 

 

Next, CDHT will

focus on advantageous segments of bioindustry,

deeply explore the requirements of key enterprises,

concentrate on innovation in financial products,

leverage the capital market for enterprise development,

continue to improve the quality and efficiency of services for the real economy,

facilitate the biological industry financial chain of CDHT to be strong and supplementary,

and continue to construct the microecology of medicine and health segments,

further driving the high-quality development of medicine and health industry.

 

 

Source: CDHT